SHRESTH: State Health Regulatory Excellence Index

13 Aug 2025

SHRESTH: State Health Regulatory Excellence Index

Recently, Ministry of Health and Family Welfare launched the State Health Regulatory Excellence Index (SHRESTH), a first-of-its-kind national initiative to benchmark and strengthen state drug regulatory systems through a transparent, data-driven framework

About SHRESTH – State Health Regulatory Excellence Index

  • SHRESTH  is a virtual gap assessment tool to evaluate, rank, and improve state drug regulatory authorities, ensuring medicine safety, quality, and efficacy.
  • Implementing Agency: Central Drugs Standard Control Organization (CDSCO)
  • Aim: Ensure safety, quality, and efficacy of medicines through a transparent, data-driven framework.

Objectives & Purpose

  • Benchmark performance of State Drug Regulatory Authorities.
  • Identify gaps via a virtual gap assessment tool; guide states towards maturity certification.
  • Ensure uniform standards across manufacturing & distribution states.
  • Promote global trust in Indian medicines; align with Pharmacy of the World vision.
  • Build on WHO ML3 status for vaccines, extend similar standards to medicines.

Structure of the Index

  • State Categories:
    • Manufacturing States – 27 indices across 5 themes:
      • Human Resources
      • Infrastructure
      • Licensing Activities
      • Surveillance Activities
      • Responsiveness
    • Primarily Distribution States/UTs – 23 indices.
  • Data Collection:
    • States submit predefined metrics to CDSCO by 25th each month.
    • Scoring done on the 1st of next month; shared with states/UTs.

Significance

  • Drug Safety Assurance: Equal quality standards for all citizens, regardless of geography.
  • Federal Cooperation: Centre–state collaboration to regulate India’s vast pharma sector.
  • Innovation Push: Encourages tech adoption in regulatory systems.
  • Global Competitiveness: Supports India’s export credibility in pharma products.

PWOnlyIAS Extra Edge

About WHO ML3 (Maturity Level 3) status

  • WHO ML3 (Maturity Level 3) status, within the context of the WHO Global Benchmarking Tool, signifies that a country’s regulatory system for medicines and other medical products is stable, well-functioning, and integrated. 
  • It indicates a high level of effectiveness in ensuring the quality, safety, and efficacy of these products.

About CDSCO

  • CDSCO is India’s National Regulatory Authority (NRA) under the Directorate General of Health Services, Ministry of Health & Family Welfare.
  • Headquarters: New Delhi. 
  • Key Responsibilities of CDSCO
    • Safety and Quality: Ensures transparency, accountability, and uniformity in services to maintain the safety, effectiveness, and quality of medical products.
    • Approval of New Drugs: Approves new drugs and oversees clinical trials.
    • Standards for Drugs: Establishes standards for drugs and controls the quality of imported drugs.
  • Collaboration with State Regulators
    • Licensing: Along with state authorities, CDSCO grants licenses for critical drugs like blood products, vaccines, IV fluids, and sera.
    • Expert Advice: Provides guidance to ensure uniform enforcement of the Drugs and Cosmetics Act across the country.

Need help preparing for UPSC or State PSCs?

Connect with our experts to get free counselling & start preparing

Aiming for UPSC?

Download Our App

      
Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">






    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.